In this regard, studies have shown that ER+ breast cancer patients with excessive activation of p-Akt (Ser473) who receive tamoxifen treatment have an increased recurrence rate and a reduced overall survival rate [35]. This evidence concerns the gene AKT1 and breast cancer.